Monte Rosa Therapeutics raises $96m to develop protein-degrading molecules
ICR and Cancer Research UK spinout closes Series B financing
Read More
Tag: Monte Rosa Therapeutics
Public launch for ICR, CR UK spinout Monte Rosa
The company aims to target cancer with new drugs that take advantage of protein degradation
Read More
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
